Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Globus Medical, Inc. stock logo
GMED
Globus Medical
$64.72
+0.6%
$52.71
$43.38
$65.74
$8.76B1.111.19 million shs1.79 million shs
Haemonetics Co. stock logo
HAE
Haemonetics
$95.86
+3.5%
$83.98
$70.74
$97.13
$4.87B0.34463,513 shs445,064 shs
Nevro Corp. stock logo
NVRO
Nevro
$9.79
-6.9%
$13.04
$9.76
$28.89
$359.11M0.96507,244 shs599,861 shs
Penumbra, Inc. stock logo
PEN
Penumbra
$212.28
+1.4%
$220.57
$180.93
$348.67
$8.23B0.57353,166 shs335,545 shs
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
$44.36
+0.7%
$33.57
$13.82
$47.00
$2.87B1.11.76 million shs1.88 million shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Globus Medical, Inc. stock logo
GMED
Globus Medical
+4.53%+27.58%+19.97%+22.98%+12.27%
Haemonetics Co. stock logo
HAE
Haemonetics
-0.71%-0.86%+6.36%+24.78%+11.42%
Nevro Corp. stock logo
NVRO
Nevro
+3.44%-5.65%-22.59%-38.66%-62.36%
Penumbra, Inc. stock logo
PEN
Penumbra
+3.12%+1.63%-6.01%-23.31%-34.56%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
+4.51%+20.49%+26.25%+89.06%+32.24%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Globus Medical, Inc. stock logo
GMED
Globus Medical
4.6561 of 5 stars
2.32.00.04.13.24.23.1
Haemonetics Co. stock logo
HAE
Haemonetics
4.2707 of 5 stars
2.32.00.04.33.12.52.5
Nevro Corp. stock logo
NVRO
Nevro
2.4219 of 5 stars
4.02.00.00.01.91.70.6
Penumbra, Inc. stock logo
PEN
Penumbra
4.829 of 5 stars
4.41.00.03.81.82.53.1
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
3.2739 of 5 stars
2.42.00.04.93.40.00.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Globus Medical, Inc. stock logo
GMED
Globus Medical
2.55
Moderate Buy$66.502.75% Upside
Haemonetics Co. stock logo
HAE
Haemonetics
2.50
Moderate Buy$108.6713.36% Upside
Nevro Corp. stock logo
NVRO
Nevro
2.00
Hold$20.00104.29% Upside
Penumbra, Inc. stock logo
PEN
Penumbra
2.70
Moderate Buy$300.6441.62% Upside
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
2.80
Moderate Buy$43.80-1.26% Downside

Current Analyst Ratings

Latest HAE, GMED, TNDM, PEN, and NVRO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/10/2024
Haemonetics Co. stock logo
HAE
Haemonetics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$115.00 ➝ $125.00
5/10/2024
Haemonetics Co. stock logo
HAE
Haemonetics
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$105.00 ➝ $107.00
5/10/2024
Haemonetics Co. stock logo
HAE
Haemonetics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
5/9/2024
Globus Medical, Inc. stock logo
GMED
Globus Medical
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$83.00 ➝ $85.00
5/8/2024
Globus Medical, Inc. stock logo
GMED
Globus Medical
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$55.00 ➝ $60.00
5/8/2024
Globus Medical, Inc. stock logo
GMED
Globus Medical
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$60.00 ➝ $63.00
5/8/2024
Globus Medical, Inc. stock logo
GMED
Globus Medical
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$64.00 ➝ $70.00
5/8/2024
Globus Medical, Inc. stock logo
GMED
Globus Medical
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
5/8/2024
Nevro Corp. stock logo
NVRO
Nevro
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$17.00 ➝ $11.00
5/8/2024
Nevro Corp. stock logo
NVRO
Nevro
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$14.00 ➝ $13.00
5/8/2024
Nevro Corp. stock logo
NVRO
Nevro
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$15.00 ➝ $12.00
(Data available from 5/10/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Globus Medical, Inc. stock logo
GMED
Globus Medical
$1.57B5.59$4.49 per share14.40$29.32 per share2.21
Haemonetics Co. stock logo
HAE
Haemonetics
$1.27B3.83$5.05 per share18.98$16.22 per share5.91
Nevro Corp. stock logo
NVRO
Nevro
$425.17M0.84N/AN/A$8.10 per share1.21
Penumbra, Inc. stock logo
PEN
Penumbra
$1.06B7.77$2.88 per share73.75$30.55 per share6.95
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
$770.01M3.72N/AN/A$4.81 per share9.22

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Globus Medical, Inc. stock logo
GMED
Globus Medical
$122.87M$1.1755.3219.731.537.83%8.82%7.20%8/1/2024 (Estimated)
Haemonetics Co. stock logo
HAE
Haemonetics
$115.40M$2.4638.9722.612.239.97%22.37%9.71%8/13/2024 (Estimated)
Nevro Corp. stock logo
NVRO
Nevro
-$92.21M-$2.57N/AN/AN/A-21.69%-30.22%-15.17%8/6/2024 (Estimated)
Penumbra, Inc. stock logo
PEN
Penumbra
$90.95M$2.3191.9053.342.068.59%7.49%5.60%8/6/2024 (Estimated)
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
-$222.61M-$2.17N/AN/AN/A-18.37%-34.38%-10.91%8/1/2024 (Estimated)

Latest HAE, GMED, TNDM, PEN, and NVRO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024Q4 2024
Haemonetics Co. stock logo
HAE
Haemonetics
$0.88$0.90+$0.02$1.40$329.53 million$343.00 million    
5/7/2024Q1 2024
Globus Medical, Inc. stock logo
GMED
Globus Medical
$0.55$0.72+$0.17$1.49$586.82 million$606.67 million    
5/7/2024Q1 2024
Nevro Corp. stock logo
NVRO
Nevro
-$1.02-$0.70+$0.32-$0.70$97.90 million$101.90 million    
5/7/2024Q1 2024
Penumbra, Inc. stock logo
PEN
Penumbra
$0.42$0.41-$0.01$0.54$274.94 million$278.70 million      
2/22/2024Q4 2023
Penumbra, Inc. stock logo
PEN
Penumbra
$0.71$0.76+$0.05$0.14$286.62 million$284.68 million      
2/21/2024Q4 2023
Nevro Corp. stock logo
NVRO
Nevro
-$0.50-$0.15+$0.35-$0.05$115.93 million$116.18 million
2/21/2024Q4 2023
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
-$0.23-$0.27-$0.04-$0.08$204.86 million$196.80 million
2/20/2024Q4 2023
Globus Medical, Inc. stock logo
GMED
Globus Medical
$0.59$0.60+$0.01$1.09$608.21 million$616.53 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Globus Medical, Inc. stock logo
GMED
Globus Medical
N/AN/AN/AN/AN/A
Haemonetics Co. stock logo
HAE
Haemonetics
N/AN/AN/AN/AN/A
Nevro Corp. stock logo
NVRO
Nevro
N/AN/AN/AN/AN/A
Penumbra, Inc. stock logo
PEN
Penumbra
N/AN/AN/AN/AN/A
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Globus Medical, Inc. stock logo
GMED
Globus Medical
0.10
4.88
2.72
Haemonetics Co. stock logo
HAE
Haemonetics
0.91
2.92
1.76
Nevro Corp. stock logo
NVRO
Nevro
0.72
6.37
4.94
Penumbra, Inc. stock logo
PEN
Penumbra
0.02
6.06
3.49
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
1.43
3.81
3.01

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Globus Medical, Inc. stock logo
GMED
Globus Medical
95.16%
Haemonetics Co. stock logo
HAE
Haemonetics
99.67%
Nevro Corp. stock logo
NVRO
Nevro
95.52%
Penumbra, Inc. stock logo
PEN
Penumbra
88.88%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
N/A

Insider Ownership

CompanyInsider Ownership
Globus Medical, Inc. stock logo
GMED
Globus Medical
24.30%
Haemonetics Co. stock logo
HAE
Haemonetics
1.79%
Nevro Corp. stock logo
NVRO
Nevro
3.20%
Penumbra, Inc. stock logo
PEN
Penumbra
5.00%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
2.20%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Globus Medical, Inc. stock logo
GMED
Globus Medical
5,000135.37 million102.48 millionOptionable
Haemonetics Co. stock logo
HAE
Haemonetics
3,03450.79 million49.88 millionOptionable
Nevro Corp. stock logo
NVRO
Nevro
1,21536.68 million35.51 millionOptionable
Penumbra, Inc. stock logo
PEN
Penumbra
4,20038.76 million36.82 millionOptionable
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
2,40064.59 million63.17 millionOptionable

HAE, GMED, TNDM, PEN, and NVRO Headlines

SourceHeadline
FDA elevates Tandem Diabetes Care’s iPhone app recall, after glitches drained insulin pump batteriesFDA elevates Tandem Diabetes Care’s iPhone app recall, after glitches drained insulin pump batteries
fiercebiotech.com - May 9 at 4:34 PM
Tandem Diabetes Care iOS app recalled after more than 200 injuriesTandem Diabetes Care iOS app recalled after more than 200 injuries
consumeraffairs.com - May 9 at 4:34 PM
Truist Financial Corp Takes $2.59 Million Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)Truist Financial Corp Takes $2.59 Million Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)
marketbeat.com - May 9 at 4:51 AM
Russell Investments Group Ltd. Purchases 109,505 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)Russell Investments Group Ltd. Purchases 109,505 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)
marketbeat.com - May 8 at 5:15 AM
Tandem Diabetes Care (NASDAQ:TNDM) PT Raised to $55.00Tandem Diabetes Care (NASDAQ:TNDM) PT Raised to $55.00
americanbankingnews.com - May 8 at 1:18 AM
Tandem Diabetes Care GAAP EPS of -$0.65 beats by $0.12, revenue of $191.67M beats by $18.13MTandem Diabetes Care GAAP EPS of -$0.65 beats by $0.12, revenue of $191.67M beats by $18.13M
msn.com - May 7 at 2:15 PM
Lisanti Capital Growth LLC Invests $3.13 Million in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)Lisanti Capital Growth LLC Invests $3.13 Million in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)
marketbeat.com - May 6 at 10:39 PM
Tandem Diabetes Care (NASDAQ:TNDM) Price Target Increased to $55.00 by Analysts at BarclaysTandem Diabetes Care (NASDAQ:TNDM) Price Target Increased to $55.00 by Analysts at Barclays
marketbeat.com - May 6 at 3:00 PM
Brokers Offer Predictions for Tandem Diabetes Care, Inc.s Q4 2025 Earnings (NASDAQ:TNDM)Brokers Offer Predictions for Tandem Diabetes Care, Inc.'s Q4 2025 Earnings (NASDAQ:TNDM)
americanbankingnews.com - May 6 at 3:52 AM
Barclays Reaffirms Their Buy Rating on Tandem Diabetes Care (TNDM)Barclays Reaffirms Their Buy Rating on Tandem Diabetes Care (TNDM)
markets.businessinsider.com - May 6 at 2:28 AM
Earnings Update: Heres Why Analysts Just Lifted Their Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Price Target To US$43.57Earnings Update: Here's Why Analysts Just Lifted Their Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Price Target To US$43.57
finance.yahoo.com - May 5 at 9:28 AM
Robert W. Baird Increases Tandem Diabetes Care (NASDAQ:TNDM) Price Target to $36.00Robert W. Baird Increases Tandem Diabetes Care (NASDAQ:TNDM) Price Target to $36.00
americanbankingnews.com - May 5 at 7:12 AM
Tandem Diabetes Care (NASDAQ:TNDM) Stock Rating Reaffirmed by Piper SandlerTandem Diabetes Care (NASDAQ:TNDM) Stock Rating Reaffirmed by Piper Sandler
americanbankingnews.com - May 5 at 5:12 AM
Tandem Diabetes Care (NASDAQ:TNDM) Sets New 52-Week High Following Analyst UpgradeTandem Diabetes Care (NASDAQ:TNDM) Sets New 52-Week High Following Analyst Upgrade
americanbankingnews.com - May 4 at 1:38 AM
Why Tandem Diabetes Stock Just Jumped 22%Why Tandem Diabetes Stock Just Jumped 22%
fool.com - May 3 at 4:34 PM
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Q1 2024 Earnings Call TranscriptTandem Diabetes Care, Inc. (NASDAQ:TNDM) Q1 2024 Earnings Call Transcript
finance.yahoo.com - May 3 at 1:09 PM
Tandem Diabetes Care (NASDAQ:TNDM) Sets New 12-Month High After Analyst UpgradeTandem Diabetes Care (NASDAQ:TNDM) Sets New 12-Month High After Analyst Upgrade
marketbeat.com - May 3 at 12:51 PM
Tandem Diabetes Care (NASDAQ:TNDM) Earns "Overweight" Rating from Piper SandlerTandem Diabetes Care (NASDAQ:TNDM) Earns "Overweight" Rating from Piper Sandler
marketbeat.com - May 3 at 11:12 AM
Tandem Diabetes (TNDM) Posts Narrower Q1 Loss, Raises 24 ViewTandem Diabetes (TNDM) Posts Narrower Q1 Loss, Raises '24 View
zacks.com - May 3 at 10:36 AM
Tandem Diabetes Care (NASDAQ:TNDM) PT Raised to $36.00Tandem Diabetes Care (NASDAQ:TNDM) PT Raised to $36.00
marketbeat.com - May 3 at 9:33 AM
Tandem Diabetes Care Shares Rise 17% on Raised 2024 Sales OutlookTandem Diabetes Care Shares Rise 17% on Raised 2024 Sales Outlook
marketwatch.com - May 3 at 8:08 AM
Tandem Diabetes Care Inc (TNDM) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and ...Tandem Diabetes Care Inc (TNDM) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and ...
finance.yahoo.com - May 3 at 8:08 AM
Q1 2024 Tandem Diabetes Care Inc Earnings CallQ1 2024 Tandem Diabetes Care Inc Earnings Call
finance.yahoo.com - May 3 at 8:08 AM
TNDM Stock Earnings: Tandem Diabetes Care Beats EPS, Beats Revenue for Q1 2024TNDM Stock Earnings: Tandem Diabetes Care Beats EPS, Beats Revenue for Q1 2024
investorplace.com - May 2 at 10:05 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Globus Medical logo

Globus Medical

NYSE:GMED
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
Haemonetics logo

Haemonetics

NYSE:HAE
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot including collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Nevro logo

Nevro

NYSE:NVRO
Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.
Penumbra logo

Penumbra

NYSE:PEN
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
Tandem Diabetes Care logo

Tandem Diabetes Care

NASDAQ:TNDM
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.